Search
Chikungunya virus Senegal strain 37997 envelope protein E1
go.drugbank.com/drugs/DB21767ApprovedInvestigationalOne of three components of a recombinant Chikungunya virus vaccine called Vimkunya.
Zapomeran
go.drugbank.com/drugs/DB21761ApprovedZapomeran, marketed under the brand name Kostaive (ARCT-154), is a self-amplifying mRNA COVID-19 vaccine for individuals 18 years and older. The self-amplifying nature of the vaccine is due to the mRNA additionally encoding a replicase e...
Antipyrine
go.drugbank.com/drugs/DB01435ApprovedAn analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver.
Belumosudil
go.drugbank.com/drugs/DB16703ApprovedInvestigational[L34754] In July 2022, Belumosudil was approved by Health Canada under the brand name RHOLISTIQ to treat the same condition in adult and pediatric patients 12 years or older.[L42925] … [A236644,L34759] Belumosudil was first approved by the FDA in July 2021, under the brand name Rezurock, for the treatment of chronic GVHD in patients who have tried and failed at least two prior lines
Levothyroxine
go.drugbank.com/drugs/DB00451ApprovedInvestigational[F4633] T<sub>4</sub> and T<sub>3</sub> act on nearly every cell of the body, but have a particularly strong effect on the cardiac system. … Levothyroxine is a synthetically produced form of thyroxine, a major endogenous hormone secreted by the thyroid gland.
Fursultiamine
go.drugbank.com/drugs/DB08966ApprovedIt has also been suggested for several non-deficiency disorders but has not yet proven useful. Fursultiamine is a vitamin B1 derivative.
Nusinersen
go.drugbank.com/drugs/DB13161ApprovedInvestigationalAn antisense oligonucleotide that induces survival motor neuron (SMN) protein expression, it was approved by the U.S.
Carfentanil
go.drugbank.com/drugs/DB01535IllicitInvestigationalVet approvedCarfentanil was first synthesized in 1974 by a team of chemists at Janssen Pharmaceutica which included Paul Janssen.
Datopotamab deruxtecan
go.drugbank.com/drugs/DB16410ApprovedInvestigational[L52130,L52220] In June 2025, it was granted an accelerated approval by the FDA for the treatment non-small cell lung cancers with EGFR mutations.[L53623] … [L52215] Datopotamab deruxtecan-dlnk (Datroway) was approved by the US FDA in January 2025 for the treatment of hormone receptor positive, HER2 negative unresectable or metastatic breast cancer.
Palopegteriparatide
go.drugbank.com/drugs/DB18676ApprovedInvestigational[L51134] Palopegteriparatide was first approved by the EMA on November 17, 2023, for the treatment of hyperparathyroidism.[L51134] On August 8, 2024, palopegteriparatide was also approved by the FDA.